Kronos Bio (NASDAQ:KRON) Trading Down 1.8% – What’s Next?

Posted by Liza Goodheart on Jan 2nd, 2025

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) dropped 1.8% during mid-day trading on Tuesday . The company traded as low as $0.90 and last traded at $0.95. Approximately 337,890 shares were traded during trading, an increase of 18% from the average daily volume of 285,876 shares. The stock had previously closed at $0.97.

Analysts Set New Price Targets

A number of brokerages recently commented on KRON. Piper Sandler lowered shares of Kronos Bio from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $6.00 to $1.00 in a research note on Thursday, November 14th. TD Cowen cut Kronos Bio from a “buy” rating to a “hold” rating in a report on Thursday, November 14th.

Check Out Our Latest Stock Analysis on Kronos Bio

Kronos Bio Trading Up 1.2 %

The stock has a market cap of $58.02 million, a P/E ratio of -0.67 and a beta of 1.83. The stock has a 50 day simple moving average of $0.94 and a 200 day simple moving average of $1.03.

Hedge Funds Weigh In On Kronos Bio

A hedge fund recently raised its stake in Kronos Bio stock. Forefront Analytics LLC boosted its position in Kronos Bio, Inc. (NASDAQ:KRON – Free Report) by 75.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 134,998 shares of the company’s stock after acquiring an additional 57,867 shares during the quarter. Forefront Analytics LLC owned 0.22% of Kronos Bio worth $167,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 64.09% of the company’s stock.

Kronos Bio Company Profile

(Get Free Report)

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.